mitoxantrone has been researched along with Bladder Cancer in 42 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects." | 9.11 | Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004) |
| "This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection." | 9.10 | A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003) |
| "To assess the efficacy of intraarterial chemoperfusion (CP) with mitoxantrone in patients with bleeding bladder cancer; comparison with the results of intraarterial embolization therapy (ET)." | 9.09 | [Locoregional chemoperfusion with mitoxantrone for palliative therapy in bleeding bladder cancer compared with embolization]. ( Dölitzsch, C; Layer, G; Schild, HH; Strunk, H; Textor, HJ; Wilhelm, K, 2000) |
| " All patients were given 4-6 doses of intravesical novantrone at the same dose level at weekly dosing interval." | 6.67 | Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. ( Albert, D; Clayton, M; Lamb, D; Lee, M; Sarosdy, M; Sharifi, R; Siami, P; Strub, M, 1991) |
| "The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects." | 5.11 | Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004) |
| "This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection." | 5.10 | A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003) |
| "Twenty-three patients with multifocal superficial bladder cancer (stage Ta - T1) unresponsive to at least 3 different intravesical agents, were enrolled in a phase II study in order to evaluate the prophylactic effects of intravesical Mitoxantrone (20 mg) after complete endoscopic resection (TUR) of any papillary tumor." | 5.10 | [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study]. ( Abatangelo, G; Bassi, PF; Carando, R; Dal Moro, F; Piazza, N; Spinadin, R; Tavolini, IM, 2003) |
| "To assess the efficacy of intraarterial chemoperfusion (CP) with mitoxantrone in patients with bleeding bladder cancer; comparison with the results of intraarterial embolization therapy (ET)." | 5.09 | [Locoregional chemoperfusion with mitoxantrone for palliative therapy in bleeding bladder cancer compared with embolization]. ( Dölitzsch, C; Layer, G; Schild, HH; Strunk, H; Textor, HJ; Wilhelm, K, 2000) |
| " High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.88 | Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. ( Bocchia, M; Cencini, E; Fabbri, A; Gentili, F; Mazzei, MA; Schiattone, L, 2018) |
| " The purpose of this study was to evaluate the efficacy of combined therapy using the cyclooxygenase inhibitor, piroxicam, and mitoxantrone against a relevant canine model of human invasive bladder cancer." | 3.72 | Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. ( Bravo, L; Chun, R; Dernell, WS; Henry, CJ; Higginbotham, ML; Jorgensen, L; Madewell, BR; McCaw, DL; Scott, MA; Sheafor, S; Straw, RC; Turnquist, SE; Tyler, JW, 2003) |
| "To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors." | 2.76 | A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. ( Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011) |
| " Dosage in subsequent cycles was adjusted according to hematologic toxicity." | 2.68 | A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. ( Carroll, PR; Ernest, ML; Fippin, LJ; Small, EJ, 1996) |
| " All patients were given 4-6 doses of intravesical novantrone at the same dose level at weekly dosing interval." | 2.67 | Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. ( Albert, D; Clayton, M; Lamb, D; Lee, M; Sarosdy, M; Sharifi, R; Siami, P; Strub, M, 1991) |
| "Non muscle invasive bladder cancer, given its high tendency to recur, coupled with an ever-present possibility to progress to potentially life-threatening muscle-invasive disease, remains a challenging clinical problem." | 2.44 | New therapeutical approaches for non muscle invasive bladder cancer. ( Bassi, P; Bongiovanni, L; Cappa, E; D'Agostino, D; Gardi, M; Pinto, F; Racioppi, M; Sacco, E; Totaro, A; Volpe, A, 2008) |
| " On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined." | 2.41 | Intravesical therapy of superficial bladder cancer. ( Melekos, MD; Moutzouris, GD, 2000) |
| "Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours." | 1.42 | Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015) |
| "Bladder and breast cancer cells and their Pgp-overexpressing MDR subclones (MGHU1, MGHU1/R, MCF-7, MCF-7/R) were given hypericin/MTZ combinations, with/without blue-light illumination." | 1.34 | Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells. ( Adigbli, DK; Farooqui, N; Loizidou, M; Macrobert, AJ; Risley, P; Sousi, E; Taylor, I; Wilson, DG, 2007) |
| " Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments." | 1.33 | Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. ( Payton, ME; Tangner, CH; Upton, ML, 2006) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| "Mitoxantrone is an effective and safe agent for the post-TUR adjuvant intravesical therapy." | 1.29 | Intravesical mitoxantrone for superficial bladder tumors. ( Arikan, N; Yaman, LS; Yaşar, B; Yurdakul, T; Zissis, NP, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (11.90) | 18.7374 |
| 1990's | 20 (47.62) | 18.2507 |
| 2000's | 12 (28.57) | 29.6817 |
| 2010's | 3 (7.14) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Gedon, J | 1 |
| Kehl, A | 1 |
| Aupperle-Lellbach, H | 1 |
| von Bomhard, W | 1 |
| Schmidt, JM | 1 |
| Inkol, JM | 1 |
| Hocker, SE | 1 |
| Mutsaers, AJ | 1 |
| Cencini, E | 1 |
| Fabbri, A | 1 |
| Schiattone, L | 1 |
| Gentili, F | 1 |
| Mazzei, MA | 1 |
| Bocchia, M | 1 |
| Garg, AD | 1 |
| Elsen, S | 1 |
| Krysko, DV | 1 |
| Vandenabeele, P | 1 |
| de Witte, P | 1 |
| Agostinis, P | 1 |
| Volpe, A | 1 |
| Racioppi, M | 1 |
| Sacco, E | 1 |
| Bongiovanni, L | 1 |
| D'Agostino, D | 1 |
| Cappa, E | 1 |
| Pinto, F | 1 |
| Gardi, M | 1 |
| Totaro, A | 1 |
| Bassi, P | 1 |
| Resta, LP | 1 |
| Pili, R | 1 |
| Eisenberger, MA | 1 |
| Spitz, A | 1 |
| King, S | 1 |
| Porter, J | 1 |
| Franke, A | 1 |
| Boinpally, R | 1 |
| Carducci, MA | 1 |
| Sweeney, CJ | 1 |
| Henry, CJ | 1 |
| McCaw, DL | 1 |
| Turnquist, SE | 1 |
| Tyler, JW | 1 |
| Bravo, L | 1 |
| Sheafor, S | 1 |
| Straw, RC | 1 |
| Dernell, WS | 1 |
| Madewell, BR | 1 |
| Jorgensen, L | 1 |
| Scott, MA | 1 |
| Higginbotham, ML | 1 |
| Chun, R | 1 |
| Huang, JS | 1 |
| Chen, WH | 1 |
| Lin, CC | 1 |
| Liaw, CC | 1 |
| Wang, CH | 1 |
| Lan, YJ | 1 |
| Lai, CH | 1 |
| Liu, JP | 1 |
| Froehner, M | 1 |
| Haase, M | 1 |
| Hakenberg, OW | 1 |
| Wirth, MP | 1 |
| Bassi, PF | 1 |
| Spinadin, R | 1 |
| Carando, R | 1 |
| Dal Moro, F | 1 |
| Abatangelo, G | 1 |
| Piazza, N | 1 |
| Tavolini, IM | 1 |
| Papatsoris, AG | 1 |
| Deliveliotis, C | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Upton, ML | 1 |
| Tangner, CH | 1 |
| Payton, ME | 1 |
| Yokoyama, M | 1 |
| Kobayashi, T | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Adigbli, DK | 1 |
| Wilson, DG | 1 |
| Farooqui, N | 1 |
| Sousi, E | 1 |
| Risley, P | 1 |
| Taylor, I | 2 |
| Macrobert, AJ | 2 |
| Loizidou, M | 1 |
| Manyak, MJ | 1 |
| Maffezzini, M | 1 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Namasivayam, S | 1 |
| Whelan, P | 1 |
| Flamm, J | 1 |
| Donner, G | 1 |
| Oberleitner, S | 1 |
| Hausmann, R | 1 |
| Havelec, L | 1 |
| Yaman, LS | 1 |
| Yurdakul, T | 1 |
| Zissis, NP | 1 |
| Arikan, N | 1 |
| Yaşar, B | 1 |
| Waxman, J | 3 |
| Barton, C | 2 |
| Serretta, V | 1 |
| Corselli, G | 1 |
| Pavone, C | 1 |
| Pavone-Macaluso, M | 1 |
| Newling, DW | 1 |
| Small, EJ | 1 |
| Fippin, LJ | 1 |
| Ernest, ML | 1 |
| Carroll, PR | 1 |
| Davies, CL | 1 |
| Duffy, PM | 1 |
| Loizidou, MC | 1 |
| Cooper, AJ | 1 |
| Vukovic, V | 1 |
| Tannock, IF | 2 |
| Thiry, M | 2 |
| Jamison, JM | 2 |
| Gilloteaux, J | 2 |
| Summers, JL | 2 |
| Goessens, G | 2 |
| Yang, CR | 1 |
| Ou, YC | 1 |
| Kuo, JH | 1 |
| Kao, YL | 1 |
| Chen, CL | 1 |
| Yean, SY | 1 |
| Horng, YY | 1 |
| Yang, CS | 1 |
| Authelet, M | 1 |
| Porter, P | 1 |
| Cornaby, AJ | 1 |
| al-Hilali, M | 1 |
| Chakrabarti, AM | 1 |
| Melekos, MD | 1 |
| Moutzouris, GD | 1 |
| Chiang, PH | 1 |
| Chiang, CP | 1 |
| Textor, HJ | 1 |
| Wilhelm, K | 1 |
| Strunk, H | 1 |
| Layer, G | 1 |
| Dölitzsch, C | 1 |
| Schild, HH | 1 |
| Ricós Torrent, JV | 1 |
| Monrós Lliso, JL | 1 |
| Iborra Juan, I | 1 |
| Casanova Ramón-Borja, JA | 1 |
| Dumont Martínez, R | 1 |
| Solsona Narbón, E | 1 |
| Biruls, R | 1 |
| James, N | 2 |
| Harrison, M | 1 |
| Rogers, H | 1 |
| Mee, D | 2 |
| Sikora, K | 2 |
| Colbeck, R | 2 |
| Abel, P | 2 |
| Thrasher, JB | 1 |
| Crawford, ED | 1 |
| Sharifi, R | 1 |
| Lee, M | 1 |
| Clayton, M | 1 |
| Lamb, D | 1 |
| Siami, P | 1 |
| Strub, M | 1 |
| Albert, D | 1 |
| Sarosdy, M | 1 |
| Stewart, DJ | 1 |
| Green, R | 1 |
| Futter, N | 1 |
| Walsh, W | 1 |
| McKay, D | 1 |
| Verma, S | 1 |
| Maroun, JA | 1 |
| Redmond, D | 1 |
| Farah, N | 1 |
| O'Donoghue, EP | 1 |
| Williams, G | 1 |
| Ballou, RJ | 1 |
| Tseng, MT | 1 |
| Quilty, PM | 1 |
| Erlichman, C | 1 |
| van Oosterom, AT | 1 |
| Fosså, SD | 1 |
| Mulder, JH | 1 |
| Calciati, A | 1 |
| de Pauw, M | 1 |
| Sylvester, R | 1 |
4 reviews available for mitoxantrone and Bladder Cancer
| Article | Year |
|---|---|
New therapeutical approaches for non muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Humans; Hyaluronic Acid; Immunotherapy; Mitoxantrone; Neoplasm Invasiveness; | 2008 |
Intravesical therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Immunotherapy; | 2000 |
[Mitoxantrone (MTX) versus mitomycin C (MMC) in the ablative treatment of Ta, T1 superficial bladder tumors. Phase III, randomized prospective study].
Topics: Female; Humans; Male; Mitomycins; Mitoxantrone; Neoplasm Staging; Prospective Studies; Remission Ind | 1992 |
Complications of intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epir | 1992 |
11 trials available for mitoxantrone and Bladder Cancer
| Article | Year |
|---|---|
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Doxorubicin; Female; Humans; Male; Middle | 2003 |
[Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Tran | 2003 |
Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adj | 2004 |
Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transitional Ce | 1995 |
Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Hu | 1995 |
Carboplatin-based chemotherapy for bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Meth | 1993 |
A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra | 1996 |
[Locoregional chemoperfusion with mitoxantrone for palliative therapy in bleeding bladder cancer compared with embolization].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Embolization, Therapeutic; Hemorrhage; Humans | 2000 |
[Mitoxantrone (MTX) versus mitomycin C (MMC) in the ablative treatment of Ta, T1 superficial bladder tumors. Phase III, randomized prospective study].
Topics: Female; Humans; Male; Mitomycins; Mitoxantrone; Neoplasm Staging; Prospective Studies; Remission Ind | 1992 |
Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer.
Topics: Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Drug Evaluation; Female; Humans; Male; Middle | 1991 |
28 other studies available for mitoxantrone and Bladder Cancer
| Article | Year |
|---|---|
BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019).
Topics: Animals; Carcinoma, Transitional Cell; Chlorambucil; Dog Diseases; Dogs; Female; Male; Meloxicam; Mi | 2022 |
Combination therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antineoplastic Combined Chemother | 2021 |
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Humans | 2018 |
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc | 2015 |
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease Models, Animal; Dogs; Female; | 2003 |
Urinary immunocytology for primary bladder B cell lymphoma.
Topics: Aged; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2004 |
Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carbon Dioxide; Carcinoma, Transitional Cell; Combined Modality Ther | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
Photochemical internalisation of chemotherapy potentiates killing of multidrug-resistant breast and bladder cancer cells.
Topics: Absorption; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Deat | 2007 |
Bladder carcinoma--the good, the bad and the ugly.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
Intravesical mitoxantrone for superficial bladder tumors.
Topics: Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxa | 1994 |
Intravesical mitoxantrone in superficial bladder tumours (Ta-T1).
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystitis; Humans; Mitoxantrone; Neoplasm | 1993 |
Intravesical mitozantrone in recurrent superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Humans; Mitoxantrone; Neoplasm Recurrence, Loca | 1995 |
Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines.
Topics: Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Epirubicin; Humans; Mitoxantrone; Tumor Cell | 1996 |
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Huma | 1997 |
Ultrastructural nucleolar alterations induced by an ametantrone/polyr(A-U) complex.
Topics: Antineoplastic Agents; Cell Nucleolus; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Immu | 1997 |
Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel | 1997 |
Ultrastructural nucleolar alterations induced by an ametantrone--poly r(A-U) complex.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleolus; DNA, Neoplasm; DNA, Ribosomal; | 1998 |
Primary lymphoma of the bladder treated successfully with mitozantrone gel.
Topics: Administration, Intravesical; Adult; Antineoplastic Agents; Gels; Humans; Lymphoma; Male; Mitoxantro | 1999 |
Intravesical mitoxantrone in superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Stud | 2000 |
Bladder cancer: inter-relationships between chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Ce | 1992 |
Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitox | 1990 |
New combination chemotherapy programme for bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Ce | 1989 |
In vitro and in vivo responses of a murine transitional cell carcinoma to doxorubicin, mitoxantrone and aclacinomycin-A.
Topics: Aclarubicin; Animals; Carcinoma, Transitional Cell; Cell Division; Cell Line; Dose-Response Relation | 1986 |
Urachal carcinoma: a response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle A | 1987 |
Growth and characterization of multicellular tumor spheroids of human bladder carcinoma origin.
Topics: Anthraquinones; Carcinoma; Cell Division; Cell Line; Humans; Mitoxantrone; Urinary Bladder Neoplasms | 1986 |
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Mal | 1985 |